UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Response, relapse and re-treatment rates and viraemia in chronic hepatitis C treated with α<inf>2</inf>-b interferon: A phase III study

Varagona, G; Brown, D; Kibbler, H; Scheuer, P; Ashrafzadeh, P; Sherlock, S; McIntyre, N; (1992) Response, relapse and re-treatment rates and viraemia in chronic hepatitis C treated with α<inf>2</inf>-b interferon: A phase III study. European Journal of Gastroenterology and Hepatology , 4 (9) pp. 707-712.

Full text not available from this repository.

Abstract

Design: Twenty patients with chronic hepatitis C were treated with 3-6 million units (MU) α 2 -b interferon three times a week for 6 months and then treated with 0.25 MU twice weekly for a further 6 months. An additional 20 patients were treated with 0.25 MU α 2 -b three times a week for 6 months and then with 3-6 MU three times a week for a further 6 months. Setting: University Department of Medicine, Royal Free Hospital and School of Medicine: a tertiary academic hospital. Selection: Forty patients with chronic non-A, non-B (NANB) hepatitis who were subsequently shown to have chronic hepatitis C were entered into the study. Thirty-six patients were evaluable. Interventions: Serum aminotransferases were monitored monthly and in selected patients hepatitis C RNA was measured in serum. Liver biopsies were assessed in responders. Follow-up ranged from 10-30 months. Main outcome measures: During the first 6 months, 50% of those started on the high dose, and 27% started on the low dose had normal aminotransferases at 12 months. Results: 19.4% of patients have not required further treatment up to 3 years after starting treatment. All patients who relapsed have responded to further treatment. Patients with sustained responses have been negative for serum HCV RNA but intermittent responders remain positive. Approximately one-fifth of patients with chronic hepatitis C have sustained responses to interferon. Conclusion: These results suggest that patients will respond to doses as low as 0.25 MU a interferon (αIFN). Approximately 20% of patients will have sustained responses to αIFN, but most will require extended treatment with interferon and remain viraemic if serum aspartate aminotransferase (AST) concentrations are elevated.

Type: Article
Title: Response, relapse and re-treatment rates and viraemia in chronic hepatitis C treated with α<inf>2</inf>-b interferon: A phase III study
URI: http://discovery.ucl.ac.uk/id/eprint/47838
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item